
Reporting from:
- Annual Meeting of the American Society of Hematology, December 4-7, 2004, San Diego
- Lymphoma: The Next Questions, April 8-9, 2005, Fort Lauderdale
- Journal of Clinical Oncology
In this edition:
The newer the better, so they say. But not this time, as we hear from Tony Green. He was looking into the treatment of essential thrombocythemia with the new agent, anagrelide. His group has discovered that superiority lies with the old treatment hydroxyurea.
Where can we go when imatinib stops working? Charles Sawyers is lighting the way for patients with chronic myeloid leukemia with the targeted therapy BMS 354 825.
Another reason has emerged why imatinib may not be the end of the road for patients with chronic myeloid leukemia who have become resistant. Francis Giles discusses the option of using the new agent AMN 107, which targets the BCR-ABL molecule in a new way.
Current proven treatment for multiple myeloma is still single agent dexamethozone, but is there scope for other therapies to be used up-front? S. Vincent Rajkumar has been working on two trials: one with thalidomide, and the other using a new drug lenalidomide.
…

Post a comment